Literature DB >> 2650018

Nephrotoxicity of aminoglycoside antibiotics.

P M Tulkens1.   

Abstract

Aminoglycoside antibiotics cause transient, usually nonoliguric, renal failure in up to 10-30% of patients treated with these drugs, and are the cause of the largest proportion of drug-induced acute nephrotoxicities. The toxic mechanism includes (i) uptake of the drug by proximal tubular cells, where it is first sequestered within lysosomes and (ii) development of a lysosomal phospholipidosis, which is rapidly associated with cell necrosis and various alterations to subcellular structure and function. Tubular necrosis is often accompanied by (and probably triggers) tubular regeneration and peritubular proliferation. The means whereby such tubular alterations eventually cause a decline in glomerular filtration and hypo-osmotic polyuria has not been established. Various in-vitro and acellular models have been designed to assess and screen for the nephrotoxic potential of aminoglycosides; of these, methods based on the analysis of aminoglycoside-phospholipid interactions appear to be the most meaningful. A number of patient- and drug-related risk factors have been identified, and their avoidance could significantly reduce the risk of nephrotoxic reactions. Because the uptake of aminoglycosides by the kidney is saturable, administration of daily doses of these drugs as one or two injections, rather than as multiple injections or by continuous infusion, may also decrease the risk for toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2650018     DOI: 10.1016/0378-4274(89)90121-5

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  14 in total

1.  Cytoplasmic and intra-nuclear binding of gentamicin does not require endocytosis.

Authors:  Sigrid E Myrdal; Katherine C Johnson; Peter S Steyger
Journal:  Hear Res       Date:  2005-06       Impact factor: 3.208

2.  Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection.

Authors:  P Van der Auwera; F Meunier; S Ibrahim; L Kaufman; M P Derde; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 3.  Mechanisms of amine accumulation in, and egress from, lysosomes.

Authors:  Stephen D B Goldman; Ryan S Funk; Roger A Rajewski; Jeffrey P Krise
Journal:  Bioanalysis       Date:  2009-11       Impact factor: 2.681

4.  Calreticulin binds to gentamicin and reduces drug-induced ototoxicity.

Authors:  Takatoshi Karasawa; Qi Wang; Larry L David; Peter S Steyger
Journal:  Toxicol Sci       Date:  2011-07-23       Impact factor: 4.849

5.  Aminoglycoside nephrotoxicity: modeling, simulation, and control.

Authors:  Florent Rougier; Daniel Claude; Michel Maurin; Alexandre Sedoglavic; Michel Ducher; Stéphane Corvaisier; Roger Jelliffe; Pascal Maire
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

6.  Aminoglycoside dosages and nephrotoxicity: quantitative relationships.

Authors:  Florent Rougier; Michel Ducher; Michel Maurin; Stéphane Corvaisier; Daniel Claude; Roger Jelliffe; Pascal Maire
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Intracellular distribution and activity of antibiotics.

Authors:  P M Tulkens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

Review 8.  Aminoglycosides: nephrotoxicity.

Authors:  M P Mingeot-Leclercq; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

9.  CLIMP-63 is a gentamicin-binding protein that is involved in drug-induced cytotoxicity.

Authors:  T Karasawa; Q Wang; L L David; P S Steyger
Journal:  Cell Death Dis       Date:  2010-11-18       Impact factor: 8.469

Review 10.  Acute kidney injury induced by antimicrobial agents in the elderly: awareness and mitigation strategies.

Authors:  Fumihiro Mizokami; Tomohiro Mizuno
Journal:  Drugs Aging       Date:  2015-01       Impact factor: 4.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.